Kane Biotech Stock Net Income
| KNE Stock | CAD 0.04 0.00 0.00% |
As of the 17th of February 2026, Kane Biotech secures the Risk Adjusted Performance of 0.0838, standard deviation of 11.77, and Mean Deviation of 5.61. Kane Biotech technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kane Biotech information ratio and potential upside to decide if Kane Biotech is priced some-what accurately, providing market reflects its recent price of 0.04 per share.
Kane Biotech Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 14.007 | Revenue | Quarterly Revenue Growth (0.99) |
| Last Reported | Projected for Next Year | ||
| Net Income | 5.5 M | 5.8 M | |
| Net Loss | -2.8 M | -3 M | |
| Net Loss | -3.5 M | -3.7 M | |
| Net Loss | (0.02) | (0.02) | |
| Net Income Per E B T | 0.78 | 1.06 |
Kane | Net Income |
The evolution of Net Income for Kane Biotech provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Kane Biotech compares to historical norms and industry peers.
Latest Kane Biotech's Net Income Growth Pattern
Below is the plot of the Net Income of Kane Biotech over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Kane Biotech financial statement analysis. It represents the amount of money remaining after all of Kane Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Kane Biotech's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kane Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 6.1 M | 10 Years Trend |
|
Net Income |
| Timeline |
Kane Net Income Regression Statistics
| Arithmetic Mean | (1,018,303) | |
| Geometric Mean | 2,450,787 | |
| Coefficient Of Variation | (343.36) | |
| Mean Deviation | 2,479,346 | |
| Median | (1,614,908) | |
| Standard Deviation | 3,496,432 | |
| Sample Variance | 12.2T | |
| Range | 11.1M | |
| R-Value | 0.37 | |
| Mean Square Error | 11.2T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | 258,400 | |
| Total Sum of Squares | 195.6T |
Kane Net Income History
Kane Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Kane Biotech is extremely important. It helps to project a fair market value of Kane Stock properly, considering its historical fundamentals such as Net Income. Since Kane Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kane Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kane Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Kane Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kane Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kane Biotech.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Kane Biotech on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Kane Biotech or generate 0.0% return on investment in Kane Biotech over 90 days. Kane Biotech is related to or competes with Aptose Biosciences, and XORTX Therapeutics. Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prev... More
Kane Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kane Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kane Biotech upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0863 | |||
| Maximum Drawdown | 58.33 | |||
| Value At Risk | (25.00) | |||
| Potential Upside | 33.33 |
Kane Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kane Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kane Biotech's standard deviation. In reality, there are many statistical measures that can use Kane Biotech historical prices to predict the future Kane Biotech's volatility.| Risk Adjusted Performance | 0.0838 | |||
| Jensen Alpha | 0.7594 | |||
| Total Risk Alpha | 0.2017 | |||
| Treynor Ratio | 0.2038 |
Kane Biotech February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0838 | |||
| Market Risk Adjusted Performance | 0.2138 | |||
| Mean Deviation | 5.61 | |||
| Coefficient Of Variation | 1083.82 | |||
| Standard Deviation | 11.77 | |||
| Variance | 138.5 | |||
| Information Ratio | 0.0863 | |||
| Jensen Alpha | 0.7594 | |||
| Total Risk Alpha | 0.2017 | |||
| Treynor Ratio | 0.2038 | |||
| Maximum Drawdown | 58.33 | |||
| Value At Risk | (25.00) | |||
| Potential Upside | 33.33 | |||
| Skewness | 0.9821 | |||
| Kurtosis | 3.7 |
Kane Biotech Backtested Returns
Kane Biotech appears to be out of control, given 3 months investment horizon. Kane Biotech has Sharpe Ratio of 0.0546, which conveys that the firm had a 0.0546 % return per unit of risk over the last 3 months. By analyzing Kane Biotech's technical indicators, you can evaluate if the expected return of 0.63% is justified by implied risk. Please exercise Kane Biotech's Mean Deviation of 5.61, standard deviation of 11.77, and Risk Adjusted Performance of 0.0838 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Kane Biotech holds a performance score of 4. The company secures a Beta (Market Risk) of 5.28, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kane Biotech will likely underperform. Please check Kane Biotech's information ratio, potential upside, as well as the relationship between the Potential Upside and day median price , to make a quick decision on whether Kane Biotech's current price movements will revert.
Auto-correlation | -0.26 |
Weak reverse predictability
Kane Biotech has weak reverse predictability. Overlapping area represents the amount of predictability between Kane Biotech time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kane Biotech price movement. The serial correlation of -0.26 indicates that nearly 26.0% of current Kane Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.26 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Kane Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Kane Biotech reported net income of 6.1 M. This is 98.21% lower than that of the Biotechnology sector and 91.29% lower than that of the Health Care industry. The net income for all Canada stocks is 98.93% higher than that of the company.
Kane Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kane Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kane Biotech could also be used in its relative valuation, which is a method of valuing Kane Biotech by comparing valuation metrics of similar companies.Kane Biotech is currently under evaluation in net income category among its peers.
Kane Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Kane Biotech from analyzing Kane Biotech's financial statements. These drivers represent accounts that assess Kane Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kane Biotech's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 18.0M | 10.9M | 11.2M | 14.7M | 13.3M | 6.9M | |
| Enterprise Value | 21.6M | 16.6M | 19.7M | 16.7M | 15.0M | 15.7M |
Kane Fundamentals
| Return On Equity | -5.97 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (63.94) % | ||||
| Current Valuation | 8.05 M | ||||
| Shares Outstanding | 167.35 M | ||||
| Shares Owned By Insiders | 43.41 % | ||||
| Number Of Shares Shorted | 11.71 K | ||||
| Price To Earning | (2.77) X | ||||
| Price To Book | 104.38 X | ||||
| Price To Sales | 11.64 X | ||||
| Revenue | 2.08 M | ||||
| Gross Profit | (95.41 K) | ||||
| EBITDA | (2.72 M) | ||||
| Net Income | 6.1 M | ||||
| Cash And Equivalents | 122.79 K | ||||
| Total Debt | 344.22 K | ||||
| Debt To Equity | 187.90 % | ||||
| Current Ratio | 0.24 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (4.11 M) | ||||
| Short Ratio | 0.06 X | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 6.69 M | ||||
| Total Asset | 2.49 M | ||||
| Retained Earnings | (34.42 M) | ||||
| Working Capital | (1.38 M) | ||||
| Net Asset | 2.49 M |
About Kane Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kane Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kane Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kane Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kane Stock Analysis
When running Kane Biotech's price analysis, check to measure Kane Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kane Biotech is operating at the current time. Most of Kane Biotech's value examination focuses on studying past and present price action to predict the probability of Kane Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kane Biotech's price. Additionally, you may evaluate how the addition of Kane Biotech to your portfolios can decrease your overall portfolio volatility.